ASP Isotopes (NASDAQ:ASPI) COO Robert Ainscow Sells 25,000 Shares

Key Points

• Insider sale: COO Robert Ainscow sold 25,000 ASP Isotopes shares at an average price of $3.90, generating $97,500. He retained 2.26 million shares, and the sale reduced his ownership by 1.10%.
• Stock and financial performance: ASPI shares rose 7.7% to $4.20, but the company reported a quarterly loss of $0.28 per share, missing estimates, despite revenue of $5.12 million exceeding expectations.
• Analyst outlook remains cautious: The stock carries a consensus “Hold” rating with an average price target of $13.00, while recent coverage includes “Sell” ratings from Wall Street Zen and Weiss Ratings.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) COO Robert Ainscow sold 25,000 shares of the firm's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $3.90, for a total transaction of $97,500.00. Following the transaction, the chief operating officer directly owned 2,256,879 shares of the company's stock, valued at approximately $8,801,828.10. This represents a 1.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Robert Ainscow also recently made the following trade(s):

• On Monday, June 8th, Robert Ainscow sold 8,438 shares of ASP Isotopes stock. The shares were sold at an average price of $7.00, for a total transaction of $59,066.00.

ASP Isotopes Stock Up 7.7%

Shares of ASPI stock traded up $0.30 during trading hours on Friday, hitting $4.20. 3,831,544 shares of the company were exchanged, compared to its average volume of 2,936,087. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.85 and a current ratio of 3.87. ASP Isotopes Inc. has a one year low of $3.51 and a one year high of $14.49. The business's 50-day simple moving average is $4.37 and its two-hundred day simple moving average is $5.20. The stock has a market capitalization of $643.90 million, a price-to-earnings ratio of -3.18 and a beta of 3.59.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.11). The firm had revenue of $5.12 million during the quarter, compared to analyst estimates of $4.47 million. ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded ASP Isotopes from a "strong sell" rating to a "sell" rating in a report on Saturday, August 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, ASP Isotopes presently has an average rating of "Hold" and an average target price of $13.00.

Institutional Investors Weigh In On ASP Isotopes

A number of institutional investors have recently modified their holdings of the business. Quantbot Technologies LP acquired a new stake in ASP Isotopes during the third quarter worth about $34,000. BNP Paribas Financial Markets boosted its stake in ASP Isotopes by 84.9% in the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock valued at $41,000 after acquiring an additional 2,548 shares during the period. State of Wyoming acquired a new position in ASP Isotopes in the first quarter valued at approximately $29,000. Allworth Financial LP bought a new position in shares of ASP Isotopes during the second quarter valued at approximately $51,000. Finally, Legal & General Group Plc grew its holdings in shares of ASP Isotopes by 30.4% during the third quarter. Legal & General Group Plc now owns 8,377 shares of the company's stock valued at $81,000 after purchasing an additional 1,953 shares during the last quarter. Institutional investors own 16.80% of the company's stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source